Easing FDA investigational new drug (IND) approvals for novel PET probes is the subject of a study recently published in Molecular Imaging and Biology and announced today by parent organization The World Molecular Imaging Society.

The University of Minnesota Medical Center – Fairview Health Services, Minneapolis, recently became the first U.S. health care facility to install the Symbia Intevo xSPECT system from Siemens Healthcare.

A U-SPECT+/CT (MILabs, The Netherlands) will be installed at Northwestern University (Chicago, IL) to deliver ultra-high resolution, high sensitivity, accurate quantification and fast scanning speed of dynamic radio-labeled molecule distributions, contributing to molecular and functional studies in CNS, cardiovascular, oncology, nephrology and reproductive biology.

Protea Biosciences, based in Morgantown, Va., is collaborating with the Carare Research Group at the University of Southampton, United Kingdom, to develop a technology that will “mine” brain cells affected by Alzheimer's in order to visualize vast numbers of molecules simultaneously.

T cell immunotherapy prompted a striking response from three out of nine women with advanced cervical cancer, including one who had extensive metastases, according to new data from the National Cancer Institute. This could offer an alternative treatment option for women with few choices remaining.

Stress myocardial perfusion scintigraphy (MPS) when conducted five years following percutaneous coronary intervention (PCI) has the potential to pinpoint addition disease in more than half of patients, according to a study published ahead of print May 14 in JACC: Cardiovascular Interventions.

The National Parkinson Foundation (NPF) is providing almost $1 million in funding for four major studies in Parkinson's disease, the Foundation announced May 22.

AZTherapies, a Boston-based biomedical company investigating Massachusetts General Hospital-licensed treatments for Alzheimer's disease (AD), announced May 23 that the FDA has cleared the path for a phase III clinical trial for ALZT-OP1, a combination of two drugs with the aim of curbing the neurodegenerative disease in its earliest stages.